In its second deal announced Wednesday morning, Roche’s Genentech is signing up with Orionis Biosciences for a molecular glue partnership in cancer and neurodegeneration.
Genentech will pay Orionis $47 million upfront, and it’s promised over $2 billion in potential downstream milestones. Orionis, a biotech company based…
Click here to view original post
